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1. Introduction 
Hepatitis C virus (HCV) infection is one of the most important causes of cirrhosis and 
hepatocellular carcinoma (HCC) and has a tremendous impact on public health worldwide. 
It is estimated that there are more than 170 million people chronically infected with HCV, 
and 3 to 4 million persons are newly infected annually. The risk for developing cirrhosis 20 
years after initial HCV infection among those chronically infected varies between studies, 
but is estimated at around 10%–15% for men and 1–5% for women. Once cirrhosis is 
established, the rate of developing HCC is at 1%–4% per year. Approximately 280,000 
deaths per year are related to HCV infection. HCV-related end-stage liver disease and HCC 
have become the leading cause for liver transplantation globally. 
HCV per se is both hepatotropic and lymphotropic. Replication of HCV in diseased 
extrahepatic organs and tissues may have cytopathic effects. It, therefore, may either trigger 
latent autoimmunity or induce an autoimmune disease de novo. The concise context of 
pathogenic mechanisms is complex and remains to be elucidated. Generally, in addition to 
established liver injury, there are multiple examples of extrahepatic metabolic disorders 
attributed to HCV infection, such as type 2 diabetes mellitus (T2DM), thyroiditis, 
glomerulopathy, mixed cryoglobulinemia, and other immunological abnormalities. These 
disorders possess some extent of impact on the disease activity, disease course, clinical 
outcomes, and treatment efficacy of current therapy. 
The aims of this chapter initially reviewed recent studies in terms of the metabolic 
manifestations of chronic HCV infection (CHC), e.g. proteinuria, T2DM, lipid abnormalities 
and metabolic syndrome to elucidate the characteristics of metabolic abnormalities and their 
clinical relevants from the aspect of epidemiological view. 
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Secondly, robust epidemiological data demonstrated the mutual link between HCV 
infection and T2DM. HCV plays a direct pathogenic role in the emergence of T2DM even in 
the early stage of liver histological changes and its diabetogenic role has been confirmed. 
Although the precise mechanisms whereby HCV infection leads to insulin resistance (IR) 
and glucose abnormalities are not fully clear, it differs from the usual pathogenesis of T2DM 
in those with non-HCV liver diseases. This chapter also tried to clarify the mutual roles of IR 
and CHC with respect to the prediction of treatment efficacy, how treatment response 
affects IR, and the role of pancreatic beta cell function in the interesting suite. 
Liver has long been regarded as the key player manipulating complex biochemical 
metabolism which is essential to maintenance of homeostasis. Recently, studies regarding 
cytokines have been prevailing worldwide in the past decade. We also introduced several 
translational studies aiming to elucidate the specific roles of the newcomers in a clinical 
setting. It will be helpful to clarify the host viral interaction and possible pathogenic 
mechanisms of this topic. 
2. The epidemiological links 
2.1 Nephropathy 
Viral hepatitis infection per se may lead to nephropathy. This uncommon extrahepatic 
manifestation might be induced either by direct cytopathic effect of virus or interplay 
between viral, host and environmental factors (Congia et al., 1996; Mazzaro et al., 2000; 
Strassburg, et al., 1996). The association between hepatitis B virus (HBV) infection and renal 
involvement, mainly membranous nephropathy, was first reported in 1971(Combes et al., 
1971). Deposition of Australia antigen-antibody complexes in glomerular basement 
membrane was identified in renal tissue of glomerulonephritis. Since then many reports 
have been made suggesting the association between HBV infection and nephropathy 
(Johnson et al., 1990; Levo et al., 1977). However, the natural history and the pathogenesis 
are not well understood but are believed to be mediated by deposition of immune 
complexes of HBV antigens in the glomeruli (Ito et al., 1981). 
On the other side, hepatitis C virus (HCV) has been shown to be a lymphotropic as well as a 
hepatotropic virus (Mazzaro et al., 2000). Replication of HCV in diseased extrahepatic 
organs and tissues may have cytopathic effects. It, therefore, may either trigger latent 
autoimmunity or induce de novo an autoimmune disease (Hadziyannis, 1997). HCV-
associated nephropathy has been postulated to be a distinct extrahepatic manifestation, 
which might be related to interplay between intrinsic renal disease, autoimmune 
abnormality, and host susceptibility (Congia et al., 1996; Garini et al., 2005; Meyers et al., 
2003). It occurs largely in the context of cryoglobulinemia (Garini et al., 2005). There are also 
quite a number of cases who do not have cryoglobulinemia but still present with one of the 
major HCV- associated nephropathy namely membranoproliferative glomerulonephritis, 
membranous nephropathy, and focal segmental glomerulosclerosis, the latter two generally 
not associated with cryoglobulinemia (Meyers et al., 2003). Barsoum et al suggested that in 
addition to a renal microstructure suitable for sieving out macromolecules associated with 
HCV infection, such as cryoglobulins and immune complexes, there are several 
circumstances in which renal cells may be a target for viral cytopathic effects. These effects 
include ingredients for HCV attachment, endocytosis, and entry. Upregulation of Toll-like 
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receptors and metalloproteinases in mesangial inflammation when there is HCV infection 
may induce injury through an aggravated immune response. HCV also can enter cells and 
replicate in B lymphocytes, and it is associated with AA amyloidosis in class VI schistosomal 
glomerulopathy (Lee et al., 2010). HCV-associated glomerulonephritis, together with 
interstitial tubular injury, may cause the subsequent CKD. 
Previous studies have shown that in persons with HCV infection, higher incidence of 
microalbuminuria and proteinuria did occur in CHC patients than in those with other forms 
of liver disease (Liangpunsakul et al., 2005; Muramatsu et al., 2000). Liangpunsakul et al 
conducted the first nested case-control study to examine the association between 
microalbuminuria and HCV infection by using the Third National Health and Nutrition 
Examination Survey (NHANES III) database. The prevalence of microalbuminuria in 
patients with HCV infection was 12.4%, which was significantly higher than in controls 
(7.5%) (P= 0.001). This difference persisted even after excluding diabetics from the analysis 
(11.4% vs. 6.7%) (P= 0.001). In nondiabetic persons with HCV infection, microalbuminuria 
occurs more often in those who aged 20 years or more (Liangpunsakul et al., 2005).  
Proteinuria has been shown to be an early diagnostic marker of kidney damage, and can 
predict the progression of renal disease in patients with diabetes as well as cardiovascular 
morbidity and mortality in diabetic and general population (Diercks et al., 2002). During the 
past decade, proteinuria has taken on a new importance, and is shown to be a cardinal sign 
and an independent risk factor for the outcome of both kidney and cardiovascular disease 
(Diercks et al., 2002). Not only is proteinuria associated with glomerular injury and loss of 
its normal permselective properties, but experimental data have demonstrated that protein-
tubular cell interactions have inflammatory and fibrogenic consequences that can contribute 
to interstitial damage and fibrosis (Keane, 2000). 
Two large-scale community studies have been conducted in 2 different HCV-endemic areas 
in Taiwan. Taiwan is a country prevalent for HBV infection and several scattered 
hyperendemic areas for HCV infection have been discovered in the past decades. The 
unique background thus provides a better scope of view to assess the difference of 
association with nephropathy between HBV and HCV infections. Lee et al recruited 54,966 
adults in a county endemic for both HBV (9.9%) and HCV (9.4%) infections. There was a 
significant increasing trend of HCV seropositivity in parallel with CKD stages, ranging from 
8.5% in stage 1 to 14.5% in CKD stages 4-5 (Figure 1) (Lee et al., 2010). 
Huang et al also conducted a prospective community-based study enrolling 10,975 subjects 
to compare the prevalence of proteinuria among adult population in another HBV (13.1%) 
and HCV (6.5%) endemic area of southern Taiwan (Yang et al., 2006; Yu et al., 2001; Yu et 
al., 2001; Huang et al., 2006). Setting proteinuria as urine dipstick test ≥1+, the prevalence of 
proteinuria among subjects seropositive for anti-HCV was significantly higher than HBV 
carriers and those negative controls. The prevalence of HCV infection was significantly 
higher among proteinuria than that of non-proteinuria individuals. Multivariate logistic 
regression analyses showed HCV infection was an independent significant factor associated 
with proteinuria. The significance remained even excluding those diabetics. By contrast, 
HBV infection did not show significant difference between proteinuria and non-proteinuria 
subjects. The robust epidemiological data demonstrated the consistent and significant 
association between HCV infection with both CKD prevalence and CKD disease severity. 
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Fig. 1. Prevalence of hepatitis C virus infection and hepatitis B virus infection based on the 
staging of chronic kidney disease (CKD). Error bars represent 95% confidence intervals. 
2.2 Type 2 diabetes mellitus 
HCV infection and Type 2 diabetes mellitus (T2DM) are two major rising epidemics 
haboring tough challenges both to the clinicians and to the health-care systems in terms of 
diagnostic, therapeutic, and economic implications (Aytaman et al., 2008). In 2003, there 
were over 194 million people diagnosed with diabetes worldwide, with an estimated 333 
million persons to be afflicted by 2025. These numbers, however, do not include those with 
undiagnosed diabetes, a population that is currently estimated to represent over 26% of the 
U.S. population alone. On the other side, HCV infection currently affects 3% of the world 
population, estimated 170 million people worldwide, leading to a substantial rise in the 
prevalence of chronic liver disease, with its enormous health and economic impacts. 
Although type 1 DM has been observed in patients treated with interferon (IFN), the 
majority of HCV-related diabetes is T2DM. 
T2DM is a common endocrine disorder encompassing multifactorial pathogenetic 
mechanisms. These mechanisms include resistance to the action of insulin, increased hepatic 
glucose production, and a defect in insulin secretion, all of which contribute to the 
development of overt hyperglycemia (Saltiel 2001). Although the precise mechanisms 
whereby these factors interact to produce glucose abnormalities are uncertain, it has been 
suggested that the final common pathway responsible for the development of T2DM is the 
failure of the pancreatic beta-cells to compensate for the insulin resistance (IR). The 
biological mechanism underlying IR or T2DM in HCV infection remains unclear. Shintani et 
al demonstrated that the ability of insulin to lower the plasma glucose level was impaired 
without gain in body weight at young age in HCV core gene transgenic mice study. A high 
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level of tumor necrosis factor-alpha was considered to be one of the bases of IR, which act by 
disturbing tyrosine phosphorylation of insulin receptor substrate (IRS)-1, a central molecule 
of the insulin-signaling cascade. These findings provided a direct experimental evidence for 
the contribution of HCV in the development of IR and in the pathogenesis of T2DM 
(Shintani et al., 2004). In addition, clinical study by Kawaguchi et al indicated an increase in 
fasting insulin levels was associated with the presence of serum HCV core protein, the 
severity of hepatic fibrosis, and a decrease in expression of IRS-1 and IRS-2 in patients with 
HCV infection. More severe IR was present in noncirrhotic patients with HCV infection than 
in patients with other liver diseases (Kawaguchi et al., 2004). HCV core-induced suppressor 
of cytokine signalling 3 may promote proteosomal degradation of IRS1 and IRS2 through 
ubiquitination, and which may be a unique mechanism of HCV-associated IR. In patients 
with undetectable levels of HCV core  protein, fasting insulin levels were within the normal 
range. In contrast, in patients with detectable levels of HCV core  protein, fasting insulin 
levels were increased. Thus, HCV core protein seemed to play a crucial role in HCV-
associated IR. 
There are strong evidence supporting an epidemiologic link between CHC and 
T2DM(Allison et al., 1994; Mason et al., 1999; Mehta et al., 2000; Wang et al., 2003; Zein et al., 
2005). The association between T2DM and CHC was first reported by Allison et al, who 
observed that the prevalence of T2DM was significantly higher in those with HCV-related 
cirrhosis than those with cirrhosis resulting from other liver diseases (Allison et al., 1994). 
The diagnosis of HCV infection and the identification of risk factors for HCV infection 
preceded the diagnosis and/or onset of T2DM in anti-HCV(+) diabetics (Knobler et al., 
2000). The prevalence of T2DM and impaired fasting glucose (IFG) was higher among HCV-
infected patients with advanced versus those with early histological disease. Advanced 
histological disease predicted T2DM/IFG after controlling for other identified risk factors 
for T2DM (Zein et al., 2005). Similar features were also observed from Asia Pacific region. 
Huang et al, in a community survey composing serological and virological features of HCV 
infection, further extended the observation that HCV viremia, but not anti-HCV 
seropositivity alone, increased the association with T2DM (Figure 2). It may imply that a 
persistent and/or active phase of HCV infection is associated with T2DM (Huang et al., 
2007). Wang et al prospectively followed 4,958 persons aged 40 years or more without 
T2DM from a community-wide cohort in southern Taiwan for 7 years. The 7-year 
cumulative incidence of those anti-HCV+ subjects was nearly 2-folds increase than those 
HBsAg+ and negative controls. After stratification by age and body mass index (BMI), the 
risk ratio for T2DM in anti-HCV+ participants increased when age decreased and BMI levels 
increased (Wang et al., 2007). Generally, the prevalence of anti-HCV seropositivity in the 
T2DM population ranged from 1.8 to 12.1%, whereas T2DM developed in 14.5 to 33.0% of 
CHC patients (Allison et al., 1994; Antonelli et al., 2005; Caronia et al., 1999; Lecube et al., 
2006; Mason et al., 1999; Mehta et al., 2003; Mehta et al., 2000; Zein et al., 2005). Different 
background in terms of ethnicity, age, prevalence of T2DM, BMI, viral load and genotype 
might contribute to the divergent results of the epidemiological observations. With respect 
to epidemiological aspect, HCV is considered to be diabetogenic and T2DM represented one 
more disease to be included in the list of established extrahepatic manifestations of HCV 
infection. 
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Fig. 2. Prevalence of T2DM among subjects with different etiologies of viral hepatitis. 
HBsAg: hepatitis B surface antigen; anti-HCV: hepatitis C virus antibodies; NBNC: neither 
HBsAg (+) nor anti-HCV (+); HCVRNA: hepatitis C virus RNA. 
The relationship between T2DM and HCV genotypes remains controversial (Knobler et al., 
2000; Lecube et al., 2006; Mason et al., 1999; Petit et al., 2001). Zignego et al demonstrated 
that HCV genotype-2a (G-2a) was specifically linked with extrahepatic manifestations such 
as cryoglobulinemia (Zignego et al., 1996). An association between G-2a infection and T2DM 
was also reported (Mason et al., 1999). However, no association was found between fasting 
insulin levels and HCV genotypes in Japanese study (Kawaguchi et al., 2004). Taiwanese 
study showed that neither HCV G-1 nor G-2 infection was significantly associated with 
T2DM (Huang et al., 2007). Recently a large-scale international collaborative study 
addressing the association between IR and viral clearance in G-1, -2 and -3 patients showed 
that IR was more common in patients with G-1 than in those with G-2/3 infection. Viral 
eradication was associated with a reduction in IR in patients infected with G-1 but not in 
those with G-2/3 infection, suggesting a causal relationship between G-1 infection and IR in 
vivo (Thompson et al., 2011). 
2.3 Metabolic disorders 
Although the precise mechanisms leading to HCV cell entry are not fully elucidated, HCV 
uptake by hepatocytes has been demonstrated to be mediated by the low-density 
lipoprotein (LDL) receptor as well as other proteins such as tetraspanin CD81, claudin-1 and 
occludin. Experiments in vitro showed competitive inhibition of binding between HCV and 
LDL-receptor by LDL-C (Monazahian et al., 1999). HCV cell entry is also mediated by 
another lipoprotein receptor, the scavenger receptor class B type I, which is responsible for 
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the entry of various classes of lipoproteins, primarily the high-density lipoproteins (HDL) 
(Negro, 2010). In addition, lipoproteins play an important role in the process of HCV 
infection since complexing of the virus to the low-density lipoprotein (VLDL-C) or LDL-C 
could promote endocytosis of HCV via the LDL receptor (Agnello et al., 1999). HCV 
infection and hypobetalipoproteinemia is characteristic in patients with HCV infection 
(Monazahian et al., 1999; Monazahian et al., 2000; Perlemuter et al., 2002). There are a lower 
cholesterol (total cholesterol, HDL-C and LDL-C) and a lower triglycerides (TG) levels in 
CHC patients than those of normal subjects (Dai et al., 2008; Siagris et al., 2006). Dai et al 
conducted a community-based mass-screening of 11,239 adults showing the subjects with 
normal serum cholesterol and TG levels had significantly higher proportion of anti-HCV+ 
than those who had elevated serum cholesterol and/or elevated TG levels. For anti-HCV+ 
patients, patients with normal serum cholesterol and TG levels had significantly higher 
proportion of positive HCV RNA than those who had elevated serum cholesterol and/or 
elevated TG levels. It is particularly noteworthy that subjects with HCV viremia have 
significantly lower serum cholesterol and TG levels than those who were negative for HCV 
RNA (Dai et al., 2008). Furthermore, a HCV genotype-based different impact on the lipid 
profile and hepatic steatosis was reported as well (Moriya et al., 2003; Serfaty et al., 2001). 
These epidemiological findings imply that HCV plays a significant role on serum lipid 
profiles and lipids are essential to the HCV life cycle. Therefore, alteration of blood lipids is 
a characteristic feature of HCV infection clinically. Recent studies demonstrated that 
successful eradication of HCV infection was associated with a significant increase in total 
cholesterol, LDL-C and TG levels in G-1, -2, and -3 infection (Tada et al., 2009). This increase 
from baseline was most pronounced in patients with G-3 infection(Thompson et al., 2011). 
Metabolic syndrome (MS) is a complicated disorder encompassing clinical features of 
obesity, hyperglycemia, hypertension, dyslipidemia and IR. It carries a high risk for future 
development of micro- and macrovascular complications. Atherosclerosis and T2DM, as 
major subsequent events of MS, are critical health issues globally (Grundy et al., 2005). 
There is groundswell evidence indicating that the atherosclerotic process is regulated by 
intervening inflammatory mechanisms. IR, heroine of the scenario in the pathogenesis of 
MS, has been increasingly recognized as playing a key role in the inflammatory processes. 
Histologically, hepatic steatosis is a common feature of CHC, which is observed in 30-70% of 
the patients (Hsieh et al., 2007; Watanabe et al., 2008). Many factors are known to be risks for 
hepatic steatosis, including DM, hyperlipidemia, and obesity (Sanyal, 2005). Apart from its 
hepatotropic characteristic, HCV infection carries a significant pathogenic effect for 
development of IR, albeit the underlying biological mechanisms are diverse and 
multifactorial. Metabolic abnormalities including liver steatosis, obesity and DM can also 
worsen the course of CHC (Moucari et al., 2007; Tarantino et al., 2006).  
The prevalence of the MS in patients with CHC varied from 4.4% in Italy, 24.7% in Taiwan 
and 51% in US veterans (Huang et al., 2009a; Keane et al., 2009; Svegliati-Baroni et al., 2007), 
suggesting that host factors such as ethnic origin could play a role in the association 
between IR and CHC (Conjeevaram et al., 2007; Serste et al., 2010). Liangpunsakul et al 
examined the relationship between nondiabetic subjects with HCV infection and 
microalbuminuria by using NHANES III database which consisted of 15,336 adults from the 
United States. There was no difference in the MS prevalence between HCV group and 
controls (Liangpunsakul et al., 2005). However, subjects with HCV infection carrying a 
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higher prevalence of MS than controls was observed from an HCV-hyperendemic area 
(>35% of anti-HCV+ prevalence in adults) in Taiwan. Those anti-HCV+ residents had a 
higher waist circumference and a higher prevalence of hypertension as the common features 
of MS (Huang et al., 2009). Further exploration is needed to clarify the complex context of 
MS with respect to different ethnicity. Furthermore, emerging lines of clinical data revealed 
that several metabolic disturbance; such as obesity, IR, and hepatic steatosis, are significant 
risk factors for decreased treatment response to pegylated IFN (PegIFN) and ribavirin 
combination therapy in CHC patients (Bressler et al., 2003; Camma et al., 2006; Romero-
Gomez et al., 2005; Watanabe et al., 2008). The association between HCV infection and MS 
could be validated by the sequential changes of MS characteristics upon treatment response 
to antiviral therapy. In addition, the difference of atherosclerotic cardiovascular disease risk 
between MS subjects with HCV infection and non-HCV subjects deserves to be further 
elucidated. 
3. Hepatitis C virus infection and type 2 diabetes mellitus 
3.1 The characteristics of glucose abnormalities in patients with chronic hepatitis C 
infection 
There has been emerging and robust data, particularly in the aspect of epidemiology, 
suggesting that a higher prevalence of T2DM among patients with HCV infection, whereas 
HCV infection is a risk factor for developing T2DM. 
T2DM is often present at least 4 to 7 years before diagnosis (Harris et al., 1992). Therefore, 
definitive diagnosis of glucose abnormalities is an important issue because it allows 
attempts to improve clinical outcomes, such as weight reduction and lifestyle modification 
(Gerstein et al., 2006; Tuomilehto et al., 2001). On the other side, almost all T2DM patients 
have experienced the prediabetic condition, namely, IFG and/or impaired glucose tolerance 
(IGT), before a definite diagnosis of T2DM was made. In addition to future DM 
development, the prediabetic condition also carries a risk for cardiovascular disease (Kannel  
et al., 1979). Generally and commonly, fasting plasma glucose (FPG) level alone is used as a 
screening test for the diagnosis of DM. However, this practice is based on the relative 
convenience and lower cost of FPG compared with a 75-gram oral glucose tolerance test 
(OGTT) (Grundy et al., 2005; Knowler et al., 2002). The discrepancy of distribution of 
glucose abnormalities before and after OGTT was estimated that 19.3–59.3% of glucose 
abnormalities remained undetected using the current IFG criteria alone (Huang et al., 1999; 
2003). 
The same scenario exists in the link between glucose abnormalities and HCV infection. 
Previous data linking HCV infection and DM mainly focused on patients with overt DM. 
Lecube et al prospectively recruited a total of 642 hispanic patients (498 anti-HCV+ and 144 
anti-HCV-) in a single center. Patients were classified as having chronic hepatitis (n = 472) or 
cirrhosis (n = 170) by means of clinical manifestations or liver biopsy. A 3 folds increase in 
the prevalence of glucose abnormalities was observed in HCV+ patients with chronic 
hepatitis in comparison with HCV- subjects (32% vs. 12%). In addition, 18% more new DM 
cases and 30% more new cases of IGT were uncovered by OGTT in anti–HCV+ patients, 
which were significantly higher than those values in anti–HCV- patients (Lecube et al., 
2004). Another case-control study recruited 683 CHC patients and 515 sex-/ age-matched 
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community-based controls were conducted in Taiwan aiming to elucidate the entire suite of 
glucose abnormalities. OGTT was performed in 522 CHC patients and 447 controls without 
known T2DM. The prevalence of normoglycemia, IGT, and T2DM in 683 CHC patients was 
27.7%, 34.6%, and 37.8%, respectively. Of note is 18.6% of CHC patients who readily met 
with DM criteria were undiagnosed (Figure 3). For those without known DM, there were 3.5 
folds increase in the prevalence of glucose abnormalities in CHC patients in comparison 
with controls (Huang et al., 2008) (Table 1). The two studies implied that CHC patients 
carried a high prevalence of glucose abnormalities and also suggested that determination of 
glucose abnormalities by OGTT should be indicated in CHC patients. It might also suggest 
that different criteria are necessary for DM diagnosis in patients with HCV infection, such as 
a lower cut-off for normoglycemia, prediabetes, and DM. 
 
Fig. 3. Distribution of glucose abnormalities among CHC patients before and after OGTT. 
OGTT: 75-g oral glucose tolerance test; PreDM: prediabetes, SDM; subclinical diabetes. 
The cause-effect interaction between a common endocrine disorder and an infectious disease 
is an important issue to elucidate. Comparison between the stages of glucose abnormalities 
and disease severity of HCV infection may pave a way to the clarification. HCV core gene 
transgenic mice study by Shintani et al demonstrated that the ability of insulin to lower the 
plasma glucose level was impaired without gain in body weight at young age (Shintani et 
al., 2004). The presence of advanced histological disease in genetically predisposed CHC 
patients was associated with a higher prevalence of DM and IFG (Zein et al., 2005). There 
was also a significant linear trend from normoglycemia to T2DM in terms of age, family 
history of T2DM, and advanced liver fibrosis in CHC patients (Huang et al., 2008). Both 
experimental and clinical studies provide the evidence that the genuine connection between 
www.intechopen.com
 
Molecular Virology 
 
42
HCV infection and T2DM is initiated at early stages of liver disease. HCV infection may 
contribute to the subtle development of glucose abnormalities at young age. 
 
Characteristics 
Anti-HCV (-) 
Controls 
Anti-HCV (+) 
patients 
P value OR, 95% CI 
Patients, n 447 552   
Age (years) 50.5 ± 13.7 52.0±12.4 NS  
Male, n (%) 222 (49.7) 268 (48.6) NS  
Normoglycemia, n (%) 289 (64.7) 189 (34.2) <0.001 0.29, 0.22-0.37 
Prediabetes, n (%) 145 (32.4) 236 (42.8) 0.001 1.56, 1.20-2.02 
Subclinical DM, n (%) 13 (2.9) 127 (23.0) <0.001 9.98, 5.55-17.9 
Table 1. Characteristics of CHC patients without known DM and controls and their glucose 
abnormalities validated by OGTT. OR: Odds ratio; CI: confidence interval 
3.2 Insulin resistance predicts response to peginterferon-alpha/ribavirin combination 
therapy in chronic hepatitis C patients 
Liver has long been regarded as the key player manipulating the homeostasis of glucose 
metabolism. As a largest reservoir of glucose, the importance of liver in the glucose 
metabolism draws its much attention from the patients with advanced liver disease. Hepatic 
diabetes was once recognized when diabetes developed in those who had advanced liver 
cirrhosis or severe liver injury, on which overt fasting hypoglycemia and/or postprandial 
hyperglycemia appeared as a common phenomenon. IR is therefore a common feature of 
some liver diseases, especially with advanced stages. To address the relationship between IR 
and liver diseases, the extent of liver injury and the impact of liver disease itself on insulin 
signalling and subsequent glucose metabolic dysregulation should be taken into 
consideration. Besides skeletal muscle and adipose tissue, liver is the major targets for the 
metabolic actions of insulin. Insulin regulates glucose homeostasis by reducing hepatic 
glucose output and by increasing the rate of glucose uptake by skeletal muscle and adipose 
tissue.  
The measurement of IR in the field of hepatology remains to be investigated in a clinical 
setting. Although the “gold standard” test for IR assessment is the hyperinsulinemic-
euglycemic clamp test. However, the difficulty of techniques and its laborious characteristic 
much embarrass the wide use of the test. The Homeostatic Model Assessment (HOMA), 
which has been used in large epidemiological studies, offers an estimate of IR by 
multiplying the FPG and insulin concentrations and dividing this product by 22.4 or 403 
when the glucose concentration is expressed as millimolar or milligrams per deciliter, 
respectively. A HOMA score close to 1 indicates normal insulin sensitivity, whilst an 
increase IR circumstance is recognized as the score over 2. HOMA has the advantage of 
requiring only a single fasting plasma sample measured for glucose and insulin. 
Nonetheless, the lack of standardization of insulin assays and the difference of IR 
standardization between races may undermine the accuracy of the measurements 
(Neuschwander-Tetri, 2008). 
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HCV may induce IR irrespective of the severity of liver disease and IR may be associated 
with severe hepatic fibrosis and contribute to fibrotic progression in CHC (Alexander, 2000; 
Dai et al., 2008; Hui et al., 2003; Petit et al., 2001; Taura et al., 2006). There was also a dose-
response relationship between HCV RNA level and the presence of IR, whilst IR was 
positively associated with the severity of hepatic steatosis (Hsu et al., 2008).  
Combination therapy with PegIFN and ribavirin has been recommended as standard 
therapy for patients with HCV infection with favorable efficacy (Hui et al., 2003; Petit et al., 
2001; Svegliati-Baroni et al., 2007). It therefore provides a wide scope of view addressing the 
correlation between HCV infection and IR. Several clinical predictors of the sustained 
virologic response (SVR), namely, HCV RNA negativity 24 weeks after treatment, to 
combination therapy have been elucidated such as the viral factors (e.g. viral G-2 or -3, 
lower pretreatment viral load) (Hui et al., 2003; Petit et al., 2001; Strader et al., 2004; 
Svegliati-Baroni et al., 2007; Taura et al., 2006) and host factors (younger age, lower BMI, 
non-African-American or Asian races and interleukin-28B polymorphisms, etc.)(Fried et al., 
2002; Strader et al., 2004; Svegliati-Baroni et al., 2007; Yu et al., 2009; Yu et al., 2011). Glucose 
abnormalities have also been suggested recently to be a risk factor for nonresponse (Muiret 
al., 2004). Romero-Gomez et al performed the first study aiming to elucidate impact of IR on 
the treatment response to PegIFN and ribavirin combination therapy. Achievement of SVR 
was significantly associated with IR. The SVR rate of G-1 patients with IR (HOMA-IR > 2) 
was 32.8%, which was significantly lower than that (60.5%) without IR (Romero-Gomez et 
al., 2005). Dai et al recruited 330 treatment-naïve CHC Taiwanese patients without overt 
diabetes validated by OGTT. Patients with high HOMA-IR achieved significantly lower rate 
of SVR than those who with low IR. The significantly lower SVR rate in high HOMA-IR 
patients than in low HOMA-IR patients was observed in G-1 patients but not in non-G-1 
patients (Figure 4). They demonstrated that HCV G-1, pretreatment HCV RNA level and 
pretreatment HOMA-IR were independent factors associated with SVR. Of note was that IR 
was associated with SVR, especially among ‘difficult-to-treat’ patients, i.e., the patients with 
G-1 infection and high pretreatment viral loads (>400,000IU/mL) (Dai et al., 2009). 
Conjeevaram et al also showed that IR was independently associated with a lower SVR rate 
(Conjeevaram et al., 2007). It is noteworthy that the mean HOMA-IR of African and 
Caucasian American with different levels of steatosis was 3.5 to 6.8, which seemed to be 
higher than 2.2 of Taiwanese patients. To develop individualized or personalized therapy 
for CHC, elucidating the changeable predictors of SVR and further manipulating them 
seems potentially achievable in addition to adjusting the regimens according to the 
unchangeable viral factors such as HCV genotype. Since IR is considered as a factor which 
can be modified and improved by various interventions, further prospective studies will be 
valuable to evaluate whether the effective approaches to improve IR before initiation of the 
combination therapy for CHC can significantly increase the SVR rate. Taken together, these 
findings suggest pretreatment HOMA-IR is a predictor for the treatment outcomes of 
combination therapy. 
Previous studies have shown that around one to two thirds of liver biopsies from CHC 
patients have histological evidence of steatosis (Dai et al., 2006; Poustchi et al., 2008; 
Romero-Gomez et al., 2005). Hepatic steatosis was associated with overweight, hepatic 
fibrosis and a high TG level. There are also associations between IR, steatosis and liver 
fibrosis in CHC patient (Conjeevaram et al., 2007; D'Souza et al., 2005; Hsieh et al., 2007; 
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Powell et al., 2005). Steatosis and fibrosis also predict for treatment response to 
PegIFN/ribavirin therapy (Heish et al., 2008; Muzzi et al., 2005). Previous study showed IR 
but not steatosis was independently associated with lower SVR rate (Conjeevaram et al., 
2007; Dai et al., 2009; Romero-Gomez et al., 2005). IR has been suggested as the cause, rather 
than the consequence, of hepatic steatosis and fibrosis in patients with HCV, particularly 
those with G-1 infection (Sud et al., 2004). The mechanisms for more obvious and important 
influence of IR than steatosis and fibrosis might need further studies in the future. 
 
Fig. 4. Sustained virological response rates to combination therapy with pegylated 
interferon-alpha and ribavirin among chronic hepatitis C patients and stratified by HCV 
genotype 1b and non-1b infection. The HOMA-IR was defined as high (>2.5 black bars) and 
low (<= 2.5 white bars). SVR: sustained virological response; HOMA: the homeostasis model 
assessment; IR, insulin resistance 
3.3 The impact of pegylated interferon plus ribavirin therapy on insulin resistance and 
beta-cell function in chronic hepatitis C patients 
PegIFN/ribavirin combination therapy is the current standard of care for the treatment of 
CHC during the past decade (Fried et al., 2002; Hsieh et al., 2007; Yang et al., 2006; Yu et al., 
2008). However, IFN is an integral player in immunity and may exacerbate an existing 
autoimmune tendency, which may subsequently precipitate immune-mediated 
abnormalities de novo (Kawaguchi et al., 2007). Emergences of IR and subsequent DM have 
been demonstrated with IFN-based therapy, although the mechanism remains to be clarified 
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(Borg et al., 2007; Chedin et al., 1996). Therefore, the interplay between IFN-based antiviral 
therapy and alteration of insulin sensitivity deserved to be elucidated. Several studies have 
suggested an association between viral clearance and/or suppression and relief of IR by 
IFN-based therapy. Reduced IR and subsequent improved glucose control after IFN therapy 
had been shown among patients with CHB and CHC infections (Tai et al., 2003). HOMA-IR 
decreased after treatment in those responders, whilst it remained unchanged in those non-
responders. Kawaguchi et al further demonstrated that clearance of HCV improves IR, beta-
cell function, and hepatic IRS1/2 expression by immunostaing, whilst there were no 
significant changes in IR and beta-cell function after antiviral therapy in those 
nonresponders and relapsers (Kawaguchi et al., 2007). Recently, results of the HALT-C 
study indicated that on-treatment virological suppression correlated with reduction in 
HOMA-IR at week 24. Huang et al further extended the observation in G-1 and -2 patients 
showing that there was no significant decline of HOMA-IR even in those responders. The 
significant decline of HOMA-IR after treatment was observed only in those patients with 
high pretreatment HOMA-IR, irrespective of SVR achievement (Huang et al., 2011). Recent 
study in a clinical trial cohort of CHC patients showed that SVR was independently 
associated with a reduction in IR in G-1 but not G-2/3 patients  (Huang et al., 2011). The 
results suggest a causal relationship between specific genotype and IR. The somewhat 
discordant results may imply that the HOMA-IR with respect to SVR may have been 
influenced by variables such as race, age, genotypes, validation methods for diabetes, cut-off 
value of IR, treatment adherence, and/or the presence of liver steatosis. Since the 
mechanisms involved in the emergence of IR are multifarious, further long-term follow-up 
study is needed to elucidate in this context. 
In addition to hyperinsulinemia, pancreatic beta-cell hyperfunction aiming to maintain 
glucose homeostasis and elevated serum insulin level is the main feature of glucose 
abnormalities. The scene is also common in HCV infection, and insulin secretion is increased 
in the initial stages of HCV infection to compensate for IR development in both experimental 
and human studies. The formulas for the HOMA model of pancreatic beta-cell function are as 
follows: HOMA-%B= fasting insulin level (μU/mL) × 360/[FPG (mg/dL) – 63]; the normal 
value for HOMA-%B was >80% (Matthews et al., 1985). Huang et al recruited 277 non-diabetic 
Taiwanese CHC patients with adequate treatment adherence and showed there was a 
significance relief of beta-cell function in CHC patients after PegIFN/ribavirin combination 
therapy, particularly in those responders. Parallel the results that there was no significant 
decline of HOMA-IR in those responders, the sequential change of beta-cell function might 
suggest that beta-cell function was recovered earlier than that of IR in CHC patients receiving 
PegIFN/ribavirin combination therapy (Huang et al., 2011). 
4. Related biomarkers 
The National Institutes of Health defined biomarker as a “characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention.” This broad definition 
includes information that can be derived from characterizing an individual’s genome, 
transcriptome, proteome, metabolome, markers of subclinical disease, and metabolic end 
products. Several aspects of effort have been performed dedicating to screen for possible 
surrogate biomarkers in terms of metabolic manifestations of CHC. 
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The precise biological mechanisms whereby HCV infection leads to metabolic abnormalities 
are not fully clear. HCV may induce a Th1 lymphocytes immune-mediated response which 
leads to activation of tumor necrosis factor (TNF)-α system and elevation of interleukin-6 
levels. Meanwhile, HCV directly causes liver steatosis. All the above events may precipitate 
to the development of liver fibrosis. TNF-α system activation, liver steatosis, and fibrosis 
contribute to the development of IR, which plays a pivotal role in the development of 
subsequent metabolic events (Lecube et al., 2006). HCV-induced inflammatory changes may 
subsequently lead to increased oxidative stress and increased peroxidation, which evoke 
systemic inflammatory responses (SIR) than other liver diseases (Lecube et al., 2006b). 
Therefore, SIR triggered by HCV and/or its subsequent immune cascades and cytokine 
storms may play a major role in the related pathogenic mechanisms in terms of liver injury 
and the unique extrahepatic manifestations (Figure 5). Meanwhile, SIR may also contribute 
either directly or indirectly to the disease course, viral response, disease severity, and 
response to antiviral treatment. Cytokines triggering, which interacts with innate and/or 
adaptive immune responses, is one of the major concealed players of the scenario. 
4.1 Retinol-binding protein 4 
For the past decades, several biomarkers have been studied as surrogates of IR. One 
example is the discovery of retinol-binding protein 4 (RBP4) as a biomarker of IR by DNA 
microarrays (Tamori et al., 2006; Yang et al., 2005). RBP4, a circulating protein that was 
highly expressed in the adipose tissue of the adipocyte-specific glucose transporter 4 
knockout mice, was demonstrated to be closely related to IR (Yang et al., 2005). IR was 
induced in mice that were either overexpressing RBP4 or were injected with recombinant 
RBP4, whereas RBP4 knockout mice showed increased insulin sensitivity. The elevated 
levels of RBP4 in both adipose tissue and serum were ameliorated when treated with 
insulin-sensitizer. Reducing serum RBP4 levels ameliorated IR in mice fed a high-fat diet. 
Graham et al extended this research to humans and showed a correlation between RBP4 
levels and the magnitude of IR in subjects with obesity, IGT, or T2DM (Graham et al., 2006). 
Serum RBP4 levels were even increased in healthy adults with a strong family history of 
DM. All these interesting findings indicate that RBP4 may serve as a new marker for IR. 
Lowering RBP4 could be a new strategy for treating T2DM was also deduced then. However, 
inconsistent observations have been postulated simultaneously and continuously since the 
discovery of its role in IR (Erikstrup et al., 2006; Janke et al., 2006; Takashima et al., 2006; von 
Eynatten et al., 2007). Although there was an association between RBP4 and steatosis in G-1 
CHC patients, Petta et al suggested RBP4 might be the expression of a virus-linked pathway to 
steatosis unrelated to IR (Petta et al., 2008). 
Liver is the primary source of RBP4 synthesis (80%), the extent of liver injury therefore 
should be considered when evaluating the correlation of RBP4 with IR (Newcomer and Ong, 
2000; Yagmur et al., 2007). Huang et al demonstrated that the increasing change of RBP level 
from normoglycemia to IGT and T2DM in healthy subjects was indistinct in CHC patients. 
No correlation of RBP4 levels with HOMA-IR in terms of different stages of glucose 
tolerance in CHC patients was observed. Intriguingly, in contrast with the parallel 
increment of IR dependent of histological grading and staging, RBP4 level was inversely 
correlated with both hepatic necroinflammatory activity and fibrosis stages (Huang et al., 
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Fig. 5. The possible pathogenic mechanisms leading to the development of insulin resistance 
and subsequent metabolic disorders. HCV triggers an immune cascades mainly mediated by 
Th1 lymphocytes. These lymphocytes increase the activation of TNF-α and elevation of 
interleukin-6 levels. HCV directly leads to steatosis, particularly in those with genotype-3 
infection. Meanwhile, HCV may also induce systemic inflammatory response and cytokine 
storms, which are potentially fibrogenic factors. All the events increase the risk for IR. 
Fibrosis may be exacerbates by the development of IR, partly by the activation of hepatic 
stellate cell. IR plays a pivotal role in the development of subsequent metabolic events. With 
respect to the development of diabetes mellitus (DM), pancreatic beta-cell hyperfunction 
aiming to maintain glucose homeostasis and elevated serum insulin level is the main feature 
before overt DM occurs. The scene of pancreatic beta-cell hyperfunction and beta-cell 
exhaustion may develop in the initial stages of HCV infection. The milieu of host factors 
(genetic predisposition, male, race, body mass index, etc), environmental factors (sedentary 
life, diet, etc) and viral factors (genotype, viral load) is also involved into the complex 
context. TNF-α: tumor necrosis factor-α; IL-6: interleukin-6; IR: insulin resistance; MS: 
metabolic syndrome; DM: diabetes mellitus 
2009). Iwasa et al also postulated the similar results in 81 G-1 CHC patients. Moreover, they 
observed that only patients who had achieved SVR had higher post-treatment RBP4 levels 
after PegIFN/ribavirin therapy (Iwasa et al., 2009). These clinical studies suggested that the 
relationship between RBP4 and IR in general population is diminished in CHC patients 
because of the negative correlation between RBP4 and disease severity. Therefore, it implied 
that RBP4 may play a limited role in the identification of IR in patients with HCV infection. 
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4.2 High-sensitivity C-reactive protein  
Acute phase reactions with elicited acute phase proteins directly or indirectly from liver are 
common features in patients with different extent of liver insults ranging from acute liver 
injury to advanced liver cirrhosis (Ramadori et al., 2001). The features of acute phase 
proteins include increased C1-inhibitor, C9, C4 and orosomucoid, whilst decreased 
transferrin and fetuin/a2HS-glycoprotein in CHC patients who responded to IFN-based 
antiviral therapy (Biro et al., 2000). In the context of cytokines, high-sensitivity C-reactive 
protein (hs-CRP) has been shown to be closely related to the occurrence of SIR (Koenig et al., 
2008). It plays as a major role in the scenario of various chronic liver diseases, such as non-
alcoholic fatty liver disease and nonalcoholic steatohepatitis (Kogiso et al., 2009; Riquelme et 
al., 2009). Serum hs-CRP levels were elevated in patients with IR and were correlated with 
MS (Ridker et al., 2003; Yudkin et al., 1999). Moreover, hs-CRP has been shown to predict 
future risks for cardiovascular disease and related mortality (Zacho et al., 2008; Zethelius et 
al., 2008). With respect to hepatological views, hs-CRP is a liver specific acute-phase protein, 
and its expression in hepatocytes is closely related with proinflammatory cytokines such as 
TNF-alpha, interleukin-1 and interleukin-6 (Kushner, 1982). The relationships between HCV 
infection and vascular atherosclerosis remain an argument of debate(Ishizaka et al., 2002; 
Moritani et al., 2005; Oyake et al., 2008). There were discrepant results of the association of 
hs-CRP level and anti-HCV seropositivity in different study groups (Floris-Moore et al., 
2007; Kalabay et al., 2004; Nascimento et al., 2005; Reingold et al., 2008; Tsui et al., 2009; 
Yelken et al., 2009). Recent studies demonstrated CHC patients had a higher serum hs-CRP 
level (> 3 mg/L, a condition indicative of a high cardiovascular risk) than healthy controls 
(Zacho et al., 2008). CHC patients with elevated hs-CRP had substantially higher levels of 
lipid profiles. However, advanced liver diseases may be associated with decreasing 
cholesterol level and the extent of liver injury should be taken into account when addressing 
this issue. Moreover, the lipid profiles are reflected by multiple factors such as race, age, 
gender, life style and meal habits. Therefore, it might be too conclusive to imply that lipid 
profiles were the major factors correlated with hs-CRP level in CHC patients. Nevertheless, 
the observation suggested that hs-CRP may be used as a complementary surrogate marker 
for cardiovascular risks in CHC patients. Further study addressing the sequential changes 
and the correlation between lipid profiles and hs-CRP in a long-term follow-up basis will be 
needed to elucidate this intriguing issue. 
Hs-CRP level was significantly decreased after PegIFN/ribavirin combination therapy, 
particularly for those with viral suppression. It may suggest that SIR in HCV infection could 
effectively be relieved after antiviral therapy, particularly in patients achieving an SVR. 
Intriguingly, among those non-SVR patients, decreases of serum hs-CRP levels were 
significantly observed only in relapsers but not in non-responders. It has been shown that 
those relapsers have more favorable outcomes after re-treatment programs compared with 
non-responders (Keeffe, 2005). The decreased SIR in relapsers, which was reflected by 
significantly decreased hs-CRP level, may in a part contribute to the favorable outcomes. It 
is noteworthy whether the non-responders carry a higher risk of developing cardiovascular 
events and it awaits further intervention. 
4.3 PI3K/Akt  
The precise mechanisms whereby SIR triggered by HCV infection is not fully clear. 
Disarrangement and/or dysregulation of intracellular signal trafficking subsequent to 
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interaction with HCV characteristic proteins have been postulated to be a major pathogenic 
mechanism of the inflammatory changes (Bowen et al., 2005). One example of such research 
is Akt. It is a 57 kDa serine/threonine protein kinase B (PKB) expressed in fibroblasts, 
adipocytes and skeletal muscle, mediates many of the downstream events of 
phosphoinositide 3-kinase (PI3K) signaling. It is a critical intracellular signal activated by 
insulin and other growth factors and is also essential for most of the metabolic effects of 
insulin (Farese et al., 2005). Upon binding of insulin to its cell surface receptor, activation of 
its tyrosine kinase activity results in the phosphorylation of multiple substrates involved in 
its downstream effector functions. Activation of PI3K and phosphoinositide-dependent 
protein kinase signalling pathway results in the activation of multiple other related 
molecules, mediates intracellular signals to regulate a variety of cellular responses, 
including anti-apoptosis, proliferation, cell cycling, protein synthesis, glucose metabolism, 
and telomere activity (Noguchi et al., 2008). Experimental studies demonstrated that HCV 
proteins can activate PI3K/Akt pathway and expression of HCV core protein increased 
hepatic stellate cell (HSC) proliferation in a PI3K/Akt dependent fashion (Bataller et al., 
2004). The increased phosphorylation correlated with increased IR to a variety of apoptotic 
stimuli (Banerjee et al., 2008; Street et al., 2005). PI3K/Akt signaling pathway was a 
concealed player involving in inflammatory process, thus contributed to HSC activation, 
liver fibrosis progression, and apotosis (Aleffi et al., 2005). Inhibition of PI3K signaling in 
HSC, which in turn reduced Akt activation, blocked the progression of liver fibrosis (Son et 
al., 2009). In addition, activation of the Akt signalling pathway has been demonstrated to 
contribute to hepatocarcinogenesis and predict outcomes of HCC in patients with HCV 
infection (Schmitz et al., 2008). Hepatic Akt expression of immunostaining was also 
significantly associated advanced fibrosis, a higher necroinflammatory activity, a lower 
BMI, a lower LDL-C and a lower gamma glutamyl transferase levels (Huang et al., 2011). 
Since HCV-induced liver fibrosis has been demonstrated to be reversible after successful 
eradication of HCV infection, a long-term follow-up study with regard to the sequential 
change of Akt expression in patients receiving antiviral therapy is needed to elucidate this 
issue. In addition, activation of the Akt signalling pathway has been demonstrated to 
contribute to hepatocarcinogenesis in patients with HCV infection. Further follow-up study 
with respect to the correlation between Akt expression and liver cancer development also 
deserves. 
4.4 Visfatin 
Adipose tissue has emerged as a major endocrine organ. These adipokines play major roles 
in key aspects of metabolism, such as energy intake and expenditure, IR, fatty acid 
oxidation, inflammation, and immunity. Visfatin, as a visceral fat-specific adipokine, is a 52 
kD protein that has been cloned already years ago as pre-B cell colony-enhancing factor 
(PBEF). Recently, visfatin was found to exert insulin-mimicking effects and may activate the 
intracellular signaling cascades for insulin(Fukuhara et al., 2005). Increasing visfatin level 
was significantly associated with T2DM(Chen et al., 2006; Dogru et al., 2007). Serum visfatin 
level was higher in obese than non-obese patients, and it was lower in non-alcoholic 
steatohepatitis patients than in those with simple steatosis or obese controls(Jarrar et al., 
2008). In addition, visfatin level was shown to predict the presence of portal inflammation in 
non-alcoholic fatty liver disease patients(Aller et al., 2009). Visfatin was preferentially 
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expressed by visceral adipose tissue compared with subcutaneous fat(Fukuhara et al., 2005). 
A positive correlation between visfatin and BMI as well as visceral fat mass has been 
reported(Hammarstedt et al., 2006). However, during the past years, contradictory results 
regarding waist circumference, glucose level, IR, visceral and subcutaneous adipose tissues 
have also been emerged in a clinical setting(Sommer et al., 2008). Berndt et al demonstrated 
that serum visfatin level did not correlate with visceral fat mass and that mRNA expression 
of the gene encoding visfatin was similar in visceral and subcutaneous adipose tissue 
(Berndt et al., 2005). Pagano et al demonstrated that serum visfatin level was decreased by 
approximately 50% in obese patients compared with controls. Furthermore, a negative 
correlation was found between serum visfatin level and BMI (Pagano et al., 2006). In the 
aspect of HCV infection, CHC patients tended to have a higher visfatin level than that of 
healthy controls. Serum visfatin level was correlated significantly with histological activity 
index scores and fibrosis stages, namely, disease severity in CHC patients (Huang et al., 
2011). It hence implied that visfatin could be a potential biomarker for prediction of disease 
severity in HCV infection. The concordant results in different entities of liver diseases 
provided evidence for previous experimental studies indicating that visfatin was involved 
into inflammatory process network (Lim et al., 2008). On the other side, the studies 
addressing the correlation between visfatin and HCV genotypes were not concordant 
(Kukla et al., 2010). There was no significant correlation between visfatin and viral load, and 
treatment response to PegIFN/ribavirin therapy. Further study is warranted to clarify in 
which a concealed player or a bystander of the necroinflammatory and fibrogenetic 
scenarios visfatin behaves. 
There was a tendency for higher visfatin levels in CHC patients with lower BMI (Huang et 
al., 2011; Kukla et al., 2010). MS was also negatively correlated with visfatin level in CHC 
patients. In addition, the extent of glucose abnormalities was not significantly correlated 
with visfatin level. These observations may imply that visfatin was not related to IR (Pagano 
et al., 2006). Kukla et al postulated that visfatin may play a dual role as a pro-inflammatory 
and/or protective factor (Kukla et al., 2010). Taken together, the speculations regarding the 
role of visfatin in CHC patients include 1) visfatin may not be one of the initiators in the 
context of metabolic derangements; 2) visfatin may not be involved into the link between 
obesity and IR in a clinical setting, at least among CHC patients. Therefore, its precise 
endocrine role deserved to be further clarified in HCV infection. 
Several cytokines, particularly adipokines, have been investigated in terms of the link 
between HCV infection, steatosis, fibrosis, and metabolic abnormalities. These include 
leptin, adiponectin, apelin, resistin, TNF-α, interleukins, etc(Liu et al., 2005; Marra et al., 
2009). It is informative and helpful for the elucidation of pathogenic mechanisms to assess 
the interaction between related biomarkers and clinical profiles of HCV infection, such as 
metabolic, virological, and histological factors. 
5. Conclusion 
Metabolic disorders are characteristic in patients with HCV infection. Besides established 
liver injury, the multiple extrahepatic metabolic disorders lead to a certain extent of impact 
on the disease activity, disease course, clinical outcomes, and treatment efficacy of current 
therapy. Enormous challenges for patient management have been arised in parallel with the 
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occurrence of these metabolic disorders. Although the precise mechanisms contributing to 
each aspect of metabolic abnormalities are not fully clarified, inspiring data and studies 
during the past decades have much enhanced our knowledge of this unique link between a 
viral hepatitis disease and many common metabolic manifestations. With the rapid 
progression of new therapy for CHC, i.e. direct acting antivirals, in the past few years, the 
interaction between HCV infection and metabolic disorders will become clearer. Meanwhile, 
recent promisng data based on genome-wide association studies largely explore our 
understanding of the impact of host susceptibility on the treatment efficacy of CHC. It may 
also pave the way for the future study regarding the genetic and/or proteomic aspects of 
metabolic abnormalities in HCV infection. On the other side, management of the metabolic 
disorders mainly depends on both pharmaceutical intervention and lifestyle modifications, 
such as exercise, diet control and weight reduction for T2DM and dyslipemia. Whether 
these interventions play a role in the disease course and prognosis of CHC patients deserves 
to be elucidated in the future. 
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